Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services
I tiakina i:
| Kaituhi matua: | |
|---|---|
| Ētahi atu kaituhi: | |
| Hōputu: | Journal Article |
| Reo: | Ingarihi |
| Ngā marau: | |
| Urunga tuihono: | Path |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Ngā tūemi rite: Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services
- Comparing Canadian and United States opioid agonist therapy policies
- Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone
- Interim opioid agonist treatment for opioid addiction: a systematic review
- Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff
- Pain in people seeking and receiving opioid agonist treatment: A systematic review and meta-analysis of prevalence and correlates
- TRENDS IN OPIOID-RELATED FATAL OVERDOSES IN MASSACHUSETTS, 1990-2003